Legal & General Group’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.3K | Buy |
1,475
+560
| +61% | +$4.15K | ﹤0.01% | 3214 |
|
|
2026
Q1 | $5.63K | Sell |
915
-23
| -2% | -$164 | ﹤0.01% | 3270 |
|
|
2025
Q4 | $6.76K | Hold |
938
| – | – | ﹤0.01% | 3315 |
|
|
2025
Q3 | $9.59K | Hold |
938
| – | – | ﹤0.01% | 3291 |
|
|
2025
Q2 | $9.75K | Sell |
938
-212
| -18% | -$2.26K | ﹤0.01% | 3295 |
|
|
2025
Q1 | $15.2K | Hold |
1,150
| – | – | ﹤0.01% | 3044 |
|
|
2024
Q4 | $20.6K | Buy |
1,150
+349
| +44% | +$7.07K | ﹤0.01% | 3010 |
|
|
2024
Q3 | $12.9K | Hold |
801
| – | – | ﹤0.01% | 3210 |
|
|
2024
Q2 | $21.6K | Buy |
801
+413
| +106% | +$9.86K | ﹤0.01% | 2990 |
|
|
2024
Q1 | $7.56K | Hold |
388
| – | – | ﹤0.01% | 3254 |
|
|
2023
Q4 | $8.02K | Hold |
388
| – | – | ﹤0.01% | 3265 |
|
|
2023
Q3 | $12.4K | Sell |
388
-28
| -7% | -$935 | ﹤0.01% | 3222 |
|
|
2023
Q2 | $14K | Buy |
+416
| New | +$14.9K | ﹤0.01% | 3254 |
|
|
2022
Q2 | – | Sell |
-317
| Closed | -$12K | – | 3633 |
|
|
2022
Q1 | $12K | Hold |
317
| – | – | ﹤0.01% | 3368 |
|
|
2021
Q4 | $31K | Hold |
317
| – | – | ﹤0.01% | 3141 |
|
|
2021
Q3 | $40K | Hold |
317
| – | – | ﹤0.01% | 3040 |
|
|
2021
Q2 | $40K | Buy |
317
+89
| +39% | +$10.6K | ﹤0.01% | 3024 |
|
|
2021
Q1 | $31K | Sell |
228
-11
| -5% | -$1.37K | ﹤0.01% | 2980 |
|
|
2020
Q4 | $22K | Hold |
239
| – | – | ﹤0.01% | 3056 |
|
|
2020
Q3 | $18K | Sell |
239
-89
| -27% | -$6.82K | ﹤0.01% | 3007 |
|
|
2020
Q2 | $28K | Buy |
+328
| New | +$29.7K | ﹤0.01% | 2927 |
|
|
2019
Q3 | – | Sell |
-211
| Closed | -$11K | – | 3400 |
|
|
2019
Q2 | $11K | Hold |
211
| – | – | ﹤0.01% | 3345 |
|
|
2019
Q1 | $15K | Buy |
211
+122
| +137% | +$7.73K | ﹤0.01% | 3179 |
|
|
2018
Q4 | $7K | Hold |
89
| – | – | ﹤0.01% | 3310 |
|
|
2018
Q3 | $42K | Hold |
89
| – | – | ﹤0.01% | 2864 |
|
|
2018
Q2 | $36K | Buy |
89
+9
| +11% | +$3.19K | ﹤0.01% | 2917 |
|
|
2018
Q1 | $25K | Sell |
80
-31
| -28% | -$8.83K | ﹤0.01% | 3053 |
|
|
2017
Q4 | $33K | Hold |
111
| – | – | ﹤0.01% | 3017 |
|
|
2017
Q3 | $62K | Buy |
111
+53
| +91% | +$28.2K | ﹤0.01% | 2845 |
|
|
2017
Q2 | $34K | Buy |
58
+39
| +205% | +$17.2K | ﹤0.01% | 3007 |
|
|
2017
Q1 | $8K | Hold |
19
| – | – | ﹤0.01% | 3212 |
|
|
2016
Q4 | $10K | Buy |
+19
| New | +$11.1K | ﹤0.01% | 3210 |
|
Other funds holding RNAC
6CM
Legal & General Group's RNAC Position: Q2 2026 in Review
Legal & General Group increased its Cartesian Therapeutics (RNAC) stake by 61% in Q2 2026, buying an estimated $4.15K and bringing the position to 1,475 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3214.
Legal & General Group first reported a position in RNAC in Q4 2016 and has held it in 32 quarters since. The position peaked at $62K in Q3 2017. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.
- Legal & General Group held 1,475 shares of Cartesian Therapeutics worth $15.3K as of Q2 2026.
- Legal & General Group bought 560 Cartesian Therapeutics shares in Q2 2026, an estimated $4.15K.
- Cartesian Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3214 holding.
- Legal & General Group first reported a position in Cartesian Therapeutics in Q4 2016 and has held it in 32 quarters since.
- Legal & General Group's Cartesian Therapeutics position peaked at $62K in Q3 2017.
- 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.
Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.